A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s immune system to generate protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from birth
- Protection possible with two-week gap before early delivery
- Vaccination in third trimester still offers significant protection for infants
Strong evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study conducted across England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that half-year window, providing strong and reliable information of the vaccine’s practical effectiveness. The study’s findings have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The scale of this research offers healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a compelling picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s critical role in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Study design and parameters
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospital admissions. The large sample size and thorough nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology assessed real-world outcomes rather than experimental conditions, providing practical evidence of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe properly. Parents commonly see their babies struggling visibly, their chests heaving as they work to get adequate oxygen into their weakened respiratory system. Whilst the majority of babies get better with palliative treatment, a limited though important number die from RSV-related complications annually, making immunisation programmes a vital health service objective for safeguarding the most vulnerable and youngest people in our communities.
- RSV triggers lung inflammation, resulting in serious respiratory problems in infants
- Half of all newborns acquire the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK infants need serious hospital treatment for RSV annually
- Small numbers of infants die from RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the value of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies via the placenta.
The communication from public health bodies stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured pregnant women that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and community involvement initiatives, though the overall statistics demonstrates consistently strong protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to reach women during pregnancy
- Geographic variations in vaccine uptake rates across England necessitate strategic intervention
- Community health services tailoring initiatives to align with local requirements and situations
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness translates into concrete gains for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this preventative solution, the 80% decrease in admissions equates to thousands of infants spared from serious illness. Parents no more face the distressing scenario of seeing their babies labour to breathe or struggle to eat, symptoms that mark severe RSV infections. The vaccine has substantially transformed the picture of neonatal breathing health, providing expectant mothers a preventative option to protect their most at-risk babies during those critical early months.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab emphasises the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women navigating their third trimester, converting what was once an predictable seasonal threat into a manageable health risk.